MedTrace Logo

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

NCT01018134 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2014-08-05

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

Desoximetasone 0.05% once daily

Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days

DRUG

Desoximetasone 0.05% twice daily

Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days

DRUG

Desoximetasone 0.25% once daily

Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days

DRUG

Desoximetasone 0.25% once daily

Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days

DRUG

Vehicle once daily

Vehicle topical spray administered to affected areas once daily for 28 days

DRUG

Vehicle twice daily

Vehicle topical spray administered to affected areas twice daily for 28 days

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018134 on ClinicalTrials.gov